Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate 03:54:45 2024-07-25 am EDT 5-day change 1st Jan Change
27.12 EUR +0.53% Intraday chart for Bayer AG +0.48% -19.42%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Bayer Wins Favorable Decision from Australia's Federal Court in Cancer Links Lawsuit MT
Australian judge dismisses glyphosate class action lawsuit against Bayer RE
Lawsuit over glyphosate risks: Australian court rules in favor of Bayer DP
Australian judge dismisses lawsuit claiming Bayer's Roundup weedkiller causes cancer RE
Bayer: new R&D center for Vividion CF
Global markets live: Bayer, CrowdStrike, Tesla, UPS, Alphabet, Tesla... Our Logo
Bayer Faces US Anti-competition Lawsuit Over Animal Medication MT
BAYER AG : JP Morgan remains Neutral ZD
Bayer Faces US Anti-competition Lawsuit Over Animal Medication MT
Global markets live: Adidas, TSMC, Vale, HSBC, J&J... Our Logo
Bayer: successful trial in prostate cancer CF
BAYER AG : JP Morgan remains Neutral ZD
Bayer: new positive data for Nubeqa CF
Bayer with trial success in prostate cancer - Analyst: As expected DP
BAYER AG : Goldman Sachs sticks Neutral ZD
Bayer's Prostate Cancer Combo Extends Progression-Free Survival in Late-stage Trial MT
Bayer's Nubeqa Meets Key Goal in Late-Stage Prostate Cancer Trial DJ
Bayer eyes wider Nubeqa use on new prostate cancer trial data RE
Bayer seeks approval extension for cancer drug Nubeqa following positive data RE
Bayer with trial success in prostate cancer - Larger patient group responsive DP
Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint CI
ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC CI
BAYER AG : UBS sticks Neutral ZD
European companies cut jobs as economy sputters RE
European Midday Briefing : Stocks Extend Rally as U.S. Rate Cut Hopes Deepen DJ
Chart Bayer AG
More charts
Logo Bayer AG
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Employees
98,189
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
26.98EUR
Average target price
35.82EUR
Spread / Average Target
+32.78%
Consensus